elsilimomab

Names

[ Name ]:
elsilimomab

Biological Activity

[Description]:

Elsilimomab (B-E8) is a IgG1 monoclonal antibody against interleukin-6 (IL-6), with a KD of 22 pM and an IC50 of 1.4 nM. Elsilimomab can be used for the research of multiple myeloma, renal cell carcinoma, and rheumatoid arthritis (RA)[1][2][3].

[Related Catalog]:

Research Areas >> Cancer

Signaling Pathways >> Immunology/Inflammation >> Interleukin Related

Research Areas >> Inflammation/Immunology

[Target]

IL-6:1.4 nM (IC50)

[In Vitro]

Elsilimomab 特异性抑制 IL-6，但不抑制 LIF (白血病抑制因子)诱导的细胞生长[2]。 Elsilimomab (20 μg/mL) 可中和人 IL-6[2]。 Cell Viability Assay[2] Cell Line: Murine B9 cells Concentration: 20 μg/mL Incubation Time: 3 days Result: B9 cells were stimulated with human IL-6, which was effectively neutralized by antibody Elsilimomab.

[References]

[1]. Lee JJ, et al. A high-affinity protein binder that blocks the IL-6/STAT3 signaling pathway effectively suppresses non-small cell lung cancer. Mol Ther. 2014 Jul;22(7):1254-1265.

[2]. Burger R, et al. Due to interleukin-6 type cytokine redundancy only glycoprotein 130 receptor blockade efficiently inhibits myeloma growth. Haematologica. 2017 Feb;102(2):381-390.

[3]. Finch DK, et al. Whole-molecule antibody engineering: generation of a high-affinity anti-IL-6 antibody with extended pharmacokinetics. J Mol Biol. 2011 Aug 26;411(4):791-807.

Chemical & Physical Properties

No Any Chemical & Physical Properties

Related Compounds

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.